Swine Mycoplasma hyopneumoniae Vaccine, Live (Strain 168) Veterinary Grade API is a lyophilized viable culture of the attenuated 168 strain of Mycoplasma hyopneumoniae, standardized for downstream incorporation into injectable suspensions, reconstitutable powders, granules, premixes, capsules, and tablet presentations. The API consists of live mycoplasma cells harvested from a master seed lot, concentrated by tangential-flow filtration, resuspended in a stabilizer matrix containing sucrose, gelatin, and phosphate buffer, and freeze-dried to a white to off-white cake. Viability is expressed in color-changing units per dose, with release titres typically controlled in the range of 10^7 CCU to 10^8 CCU per dose; the exact minimum is product-specific and must be confirmed against the batch certificate. Residual moisture is controlled at ≤3.0% w/w by Karl Fischer titration to preserve lyophilized viability. Identity is verified by species-specific PCR, and extraneous mycoplasma and bacterial sterility are tested according to 9 CFR 113.28 and 21 CFR 610.12 or the equivalent Chinese Veterinary Pharmacopoeia method. Because the active fraction is a living organism, formulation conditions that are trivial for chemical APIs—terminal filtration, elevated drying temperatures, or prolonged aqueous holding—can introduce disproportionate titre loss.

Which Release Specifications Govern the Freeze-Dried API?

A practical release specification for the lyophilized API is provided below. These values are representative of commercial live Mycoplasma hyopneumoniae strain 168 material; they are not global maxima and must be replaced by the approved specification in the importing jurisdiction. The table is a compliance checklist for incoming quality control, not a replacement for process validation.

Incoming quality control should include a viability loss challenge during reconstitution with the intended diluent; the material should not be released solely on pre-lyophilization titre.

For dry oral dosage forms such as premix, granules, and capsules, the lyophilized API must be blended in a humidity-controlled suite with air dewpoint below −20 °C. A tumble blender operating at 4–8 rpm is preferable to high-shear mixers because prolonged mechanical energy and local temperature rise above 20 °C can reduce viable CCU recovery. Blend times should be limited to 15–20 min, and the blend should be discharged directly into desiccated drums. Tablets are more problematic: direct compression of live Mycoplasma hyopneumoniae 168 is not a standard registered presentation, and published quantitative compaction data for this specific strain are limited. If tablet development is pursued, compaction force must be kept below the threshold at which the stabilizer matrix undergoes shear-induced amorphization, because amorphous sucrose can absorb moisture and destabilize the cell membrane. Capsule filling with a dosator-type machine is less destructive than tableting, but empty capsule shells must be preconditioned to a loss-on-drying below 5.0% w/w to avoid moisture transfer to the API.

When Lyophilization Parameters Are Transferred to Contract Manufacturing Lines

Technology transfer of the strain 168 API lyophilization cycle requires careful matching of shelf heat-transfer uniformity, condenser capacity, and vial load density. A typical conservative cycle for live Mycoplasma hyopneumoniae in a sucrose–gelatin matrix uses a freezing ramp of 0.3–0.5 °C/min to −40 °C, primary drying at a shelf temperature of −25 °C to −15 °C at chamber pressure 0.10–0.20 mbar, and secondary drying not exceeding 25 °C for 6–10 h. On a production freeze dryer with a shelf area of 10 m², edge vials can run 1.0–2.5 °C hotter than center vials, producing a batch moisture distribution from 1.8% w/w to 3.2% w/w if the cycle is not optimized. If the product temperature exceeds the collapse temperature of the stabilizer matrix, microcollapse creates dense regions that slow reconstitution and may trap residual water near the cake surface. The observed failure mode is not a visible collapse but a bimodal viability distribution across the chamber; therefore, process qualification should include full-rack moisture mapping and CCU testing at edge, center, and door positions. Condenser overload must also be avoided because wet chamber conditions during secondary drying can rehydrate exposed sucrose at the cake surface, reducing titre stability during storage.

Residual Moisture and Thermal Stability Boundaries in Lyophilized Live Culture Handling

After lyophilization, the API enters a cold-chain-dependent stability envelope. Storage is typically controlled at ≤−15 °C for long-term inventory; excursions above 8 °C for more than 24 h may accelerate membrane lipid oxidation and reduce viable titre. Freeze–thaw cycling of the lyophilized cake is not applicable if containers remain sealed, but opening and re-closing under uncontrolled humidity introduces moisture; the API should be handled only in a relative humidity below 30% or under dry nitrogen. Residual moisture above 3.5% w/w is a known destabilizer because unfrozen water acts as a plasticizer in the sucrose glassy matrix, lowering the glass transition temperature and allowing molecular mobility that can damage membrane-bound proteins. The live organism is sensitive to alcohols, quaternary ammonium compounds, and chlorhexidine; contact with these agents on cleanroom surfaces or equipment must be avoided. Aqueous processing after reconstitution is addressed below, but the fundamental boundary is that the API should not be held as a reconstituted solution outside 2–8 °C for more than 2 h unless a viability-loss study demonstrates otherwise.

Reconstitution of the lyophilized API into injectable solutions uses sterile diluent chilled to 2–8 °C. The reconstituted suspension must be swirled gently; high-shear mixing or vortexing can create cavitation and rapid local temperature spikes that reduce CCU titre. Terminal filtration through a 0.22 µm membrane is not feasible because Mycoplasma hyopneumoniae cells are near the filter cut-off, producing either retention, deformation, or unpredictably low recovery. Therefore, upstream aseptic processing is mandatory. For intramuscular or intrapulmonary injection, the diluent composition should be limited to sterile phosphate-buffered saline or the manufacturer’s specified diluent; adding dextrose or hypertonic saline can alter osmotic balance and damage the cell membrane. In-line mixing during filling should be validated with a viability loss acceptance criterion of not more than 0.3 log10 CCU per filling hour. Any use of silicone-based lubricants in filling equipment should be assessed for compatibility because silicone oil can create hydrophobic interfaces that adsorb viable cells and reduce dose uniformity.

Live Attenuated Strain 168 Differs From Inactivated Bacterins in Immunological Mechanism

Unlike inactivated whole-cell bacterins, the live strain 168 API is designed to replicate at the respiratory mucosal surface. This replication can stimulate local secretory IgA and cell-mediated responses that are difficult to achieve with oil-adjuvanted killed products given intramuscularly. Inactivated bacterins often require two-dose primary immunization and rely on depot adjuvants; they may produce injection-site reactions and do not consistently reduce mycoplasma colonization. The live product is cold-chain-dependent and may be incompatible with certain antimicrobial therapies during vaccination, whereas inactivated bacterins are more robust. The following matrix summarizes key differences.

Assessing Viability Loss in Aqueous Suspensions After Reconstitution

Viability loss after reconstitution is concentration-dependent, temperature-dependent, and time-dependent. A viable count decline of 0.2–0.5 log10 CCU within the first 30 min may occur when the diluent is above 15 °C; below 8 °C the decline is typically slower but should be verified for the exact stabilizer matrix. For injectable production, holding times between reconstitution and final fill should be short; if the process includes a mixing vessel, the vessel jacket should be set to 2–8 °C and the suspension should be gently agitated at 20–40 rpm. Sampling for in-process CCU should occur at the beginning, middle, and end of the fill to detect spatial or temporal titre gradients. Oral solutions present a larger challenge because gastric pH below 4.0 is expected to inactivate the live cells unless enteric protection or buffering is provided. Published data for enteric-coated live Mycoplasma hyopneumoniae strain 168 in monogastric swine are limited; therefore, oral solution or tablet development should be treated as an unproven formulation pathway until challenge studies demonstrate pulmonary or systemic immune response.

Compared with recombinant subunit vaccines or DNA-delivered antigens, the live 168 API contains the native multicomponent surface architecture of Mycoplasma hyopneumoniae, including membrane lipoproteins and adhesins involved in colonization. This broader antigenic profile may support blocking of ciliary binding, but it also creates stability and purity requirements that are absent from a defined-protein vaccine. Recombinant subunit preparations can be terminally sterilized or filtered and are usually stored as refrigerated liquids with greater margin for temperature excursions; the live API cannot be sterilized after formulation. The 168 strain also differs from other attenuated live Mycoplasma hyopneumoniae strains in geographic origin, attenuation markers, and registered route; direct interchangeability should never be assumed because each master seed has distinct residual virulence and shedding characteristics. Batch-to-batch variance in CCU titre and mycoplasma cell clumping is a recognized production limitation, requiring robust concentration and lyophilization controls rather than simple optical density compensation.